Weiss Ratings Reiterates “Sell (E+)” Rating for 2seventy bio (NASDAQ:TSVT)

2seventy bio (NASDAQ:TSVT)‘s stock had its “sell (e+)” rating restated by analysts at Weiss Ratings in a research report issued on Saturday,Weiss Ratings reports.

2seventy bio Price Performance

Shares of TSVT traded up $0.17 during mid-day trading on Friday, reaching $2.61. The company had a trading volume of 380,020 shares, compared to its average volume of 398,038. The company has a market capitalization of $134.65 million, a P/E ratio of -1.40 and a beta of 1.76. 2seventy bio has a twelve month low of $2.35 and a twelve month high of $6.40. The company’s 50-day moving average is $3.28 and its 200-day moving average is $4.15.

Institutional Investors Weigh In On 2seventy bio

Institutional investors and hedge funds have recently made changes to their positions in the company. Western Standard LLC acquired a new stake in shares of 2seventy bio during the 3rd quarter worth about $1,350,000. Marshall Wace LLP increased its holdings in shares of 2seventy bio by 50.4% during the second quarter. Marshall Wace LLP now owns 667,023 shares of the company’s stock worth $2,568,000 after buying an additional 223,408 shares in the last quarter. BBR Partners LLC raised its stake in shares of 2seventy bio by 620.0% in the third quarter. BBR Partners LLC now owns 180,000 shares of the company’s stock valued at $850,000 after acquiring an additional 155,000 shares during the last quarter. Stonepine Capital Management LLC acquired a new position in shares of 2seventy bio in the 2nd quarter worth approximately $385,000. Finally, Susquehanna Fundamental Investments LLC grew its position in 2seventy bio by 39.1% during the 2nd quarter. Susquehanna Fundamental Investments LLC now owns 192,319 shares of the company’s stock worth $740,000 after acquiring an additional 54,076 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.